Sernova Corp. Forecasted to Post FY2027 Earnings of ($0.02) Per Share (TSE:SVA)

Sernova Corp. (TSE:SVA) – Equities researchers at Leede Financial upped their FY2027 earnings per share estimates for shares of Sernova in a research report issued on Thursday, September 12th. Leede Financial analyst D. Loe now forecasts that the company will earn ($0.02) per share for the year, up from their prior estimate of ($0.03). Leede Financial currently has a “Speculative Buy” rating and a $1.50 target price on the stock. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share.

Sernova (TSE:SVA) last released its quarterly earnings results on Friday, June 14th. The company reported C($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of C($0.03).

Several other equities analysts have also issued reports on the company. Ventum Financial decreased their target price on Sernova from C$3.00 to C$2.50 and set a “buy” rating on the stock in a research note on Friday. Ventum Cap Mkts raised Sernova to a “strong-buy” rating in a research report on Thursday, September 12th.

Sernova Stock Performance

TSE SVA opened at C$0.25 on Monday. The stock has a fifty day simple moving average of C$0.27 and a 200-day simple moving average of C$0.37. Sernova has a twelve month low of C$0.20 and a twelve month high of C$0.83. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The stock has a market cap of C$79.48 million, a PE ratio of -1.88 and a beta of 1.38.

Insider Buying and Selling at Sernova

In other Sernova news, Director Steven Sangha sold 930,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of C$0.24, for a total value of C$223,200.00. Insiders have purchased 359,600 shares of company stock valued at $92,771 in the last quarter. Corporate insiders own 12.98% of the company’s stock.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.